Novartis Poised To Be First To Market With IL-17 Blocker For Psoriasis
This article was originally published in The Pink Sheet Daily
The Swiss drug maker filed its IL-17 inhibitor secukinumab in the U.S. and Europe, providing an opportunity to beat rivals Amgen and Eli Lilly to the market with a first-in-class drug. Secukinumab is one of two drugs Novartis filed in the fourth quarter, the firm reported during a year-end earnings call Jan. 29.
You may also be interested in...
Amgen talked up its international expansion efforts while Novartis painted a picture of the growing importance of emerging markets to its bottom line. And both companies see biosimilars as a key play in emerging markets.
Novartis sells six OTC brands, including Bufferin, to focus resources on core consumer health products. The firm also is realigning its consumer health supply chain, including restructuring its Lincoln, Nebraska, manufacturing plant, where the workforce will be cut 40%.
Novartis released mixed Phase III data on its heart failure candidate at the American Heart Association Scientific Sessions, showing the drug reduced symptoms of acute heart failure but failed to demonstrate an improvement on a second endpoint, cardiovascular death and hospital stays at 60 days.